Recon: Gilead Wins Reversal of Hep C Patent Verdict; Merck CEO Speaks Out on Trump

• Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict (Reuters) (Stat)
• Novartis readies to auction U.S. generic pills business: sources (Reuters)
• FDA Okays First Concussion Blood Test--but Some Experts Are Wary (Scientific American)
• FDAAA TrialsTracker: A live informatics tool to monitor compliance with FDA requirements to report clinical trial results (Paper) (Tracker)
• The C.E.O. Who Stood Up to President Trump: Ken Frazier Speaks Out (NY Times-$)
• AstraZeneca's immunotherapy drug wins key lung cancer approval (Reuters) (Focus) (FT-$)
• Targeted protein degraders are redefining how small molecules look and act (C&EN)
• Did Pox Virus Research Put Potential Profits Ahead of Public Safety? (NPR)
• Is California Turning Stem Cells Into Dollars or Debts? (Bloomberg)
• Apple’s Move to Share Health Care Records is a Game Changer (Wired)

• Europe’s chemical makers look back fondly on 2017 (C&EN)
• WHO warns over measles immunisation rates as cases rise 400% across Europe (Guardian)
• Lessons from Ranbaxy: Suffocating Silence Prevented Us From Questioning the Rot in the System (The Wire)
• Greek judges call for calm over Novartis scandal (Euractiv)
• Japanese firms push into cell therapy (C&EN)
• NICE gives three nods in thyroid cancer (PharmaTimes)
• Malawi cholera cases pass 500, eight people dead (Reuters)
• World leaders join new drive to beat noncommunicable diseases (WHO)
• Maha FDA urges CDSCO to consider industry plea towards easing out repeated joint inspections on loan licenses (PharmaBiz)

• Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact (Endpoints)
• Tetraphase and Their Troubles (In the Pipeline)
• The Deeply Human Core of Roche's $2.1B Tech Acquisition - And Why They Did It (Forbes)
• Allergan, Others Cough Up $9M In Product-Hopping Suit (Law360-$)
• Momenta, Sandoz Can't Nix Drug Antitrust Suit, Court Told (Law360-$)
• Vertex offers ‘portfolio approach’ to secure access to CF meds (PharmaTimes)

• New Data Demonstrates Long-Term Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis Treated with Janssen’s Tremfya (guselkumab) (Press)
• Otezla (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers (Press)
• AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting (Press) (PMLive)
• Scientists Explore Ties Between Alzheimer's And Brain's Ancient Immune System (NPR)
• Major Threat to Malaria Control Programs by Plasmodium falciparum Lacking Histidine-Rich Protein 2, Eritrea (CDC)
• New C diff guidelines incorporate fecal transplant (CIDRAP)

• FDA's Root Causes and Use Error (MDDI)
• BD Accuses Cytek of Stealing Trade Secrets (MDDI)
• Boston Scientific IP Attys Must Defend Doc-Redact Request (Law360-$)

• FDA’s bigger piggy bank (BioCentury)
• FTC Nominees Open To Reviewing Past PBM Mergers; Simons Wants Task Force To Monitor Drug Prices (InsideHealthPolicy-$)

• FDA Advisory Committee Calendar

• Breakthrough over growing human organs in animals (Financial Times-$)
• Grandmother loses life-savings for stem cell 'cure' at St. Louis clinic (KSDK)
• Tango classes, ukulele lessons: the rise of “social prescriptions” (The Economist)